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Vaccines play an increasingly important role in preventing and treating diseases ranging from infectious 
pathogens to cancer because these technologies harness the specificity of the immune system to clear disease 
without targeting the body’s own cells. To realize these goals, new understanding of adjuvants – molecules 
added to vaccines to enhance function – is needed to support design of next-generation vaccines that elicit 
responses tailored for specific diseases. We recently reported a simple nanotechnology platform based on self-
assembly of peptide antigen and a molecular toll-like receptor agonist (TLRa) to create modular vaccine designs 
(ACS Nano 2016, ACS Nano 2015). These structures – termed immune polyelectrolyte multilayers (iPEMs) – 
juxtapose antigen and TLRa at high densities, and offer 100% cargo loading since no carrier component is 
needed. This modularity also creates the possibility of rationally designing iPEMs that trigger multiple immune 
pathways with distinct control over the relative activation levels. In cancer, for example, activating multiple innate 
pathways has been linked to improved patient outcomes in human clinical trials. To exploit iPEMs in this 
manner, we designed iPEM architectures incorporating a conserved human cancer antigen (Trp2), and a range 
of molecularly-defined TLRa that spanned different TLRa classes and species (i.e., mouse and human): 
agonists for TLR3, TLR9, and TLR13. iPEMs were assembled from Trp2 and one, two, or three TLRas, or 
alternatively, using two different TLRas at varying compositions. To form carrier free capsules using these 
design schemes, Trp2 was appended with cationic amino acids, then adsorbed onto a sacrificial colloidal 
template, with alternating adsorption steps employing the specified TLRas (anionic). Centrifugation and wash 
steps were performed after each adsorption, then the template was dissolved using a chelator (EDTA) to form 
carrier-free capsules formed entirely from tumor peptide and each TLRa composition. All components were 
labeled to facilitate measurement of composition by fluorimetry and confocal microscopy. Using this approach, 
we discovered iPEMs could be assembled from any combination of Trp2 and the TLRas (Fig. 1A). 
Quantification revealed further confirmed iPEM capsules consisting of the corresponding peptide antigen and 
TLRa ligands (Fig. 1B). iPEMs incubated with primary dendritic cells isolated from BL6 mice revealed a high 
degree of colocalization of each iPEM component within cells. For example, iPEMs consisting of Trp2 and all 
three TLRas revealed that 90% of cells positive for at least one iPEM component were positive for all four 
components (Fig. 1C). Compared with equivalent free mixtures, iPEMs drove synergistic activation of DCs 
measured using flow cytometry for common surface activation makers (e.g., CD80, CD40, CD86) (Fig. 1D). 
Importantly, iPEMs also allowed modular control of TLR signaling, revealed using iPEMs built from Trp2 while 
varying the input ratio of TLR3a:TLR9a to control the final composition. iPEMs with a high TLR3a:TLR9a ratio 
triggered a high 
level of TLR3 
signaling (Fig. 
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Figure 1 – A) Modular assembly of Trp2 and combinations of TLRas in iPEMs. B) 
Quantification of TLRa loading. C) iPEMs deliver multiple signals to DCs, and D) drive 
synergistic responses relative to equivalent free signals. E) iPEMs can be prepared 
with distinct TLRa compositions, leading to tunable activation of each TLR signaling 
pathway. 
